Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Real-time Quotes & News
Home
> Real-time Quotes & News
Real-time Quotes
Product
Bid
Ask
High
Low
Previous Close
{{ quote.symbol }}
{{ quote.bid }}
{{ quote.ask }}
High
{{ quote.high }}
Low
{{ quote.low }}
Previous Close
{{ quote.previousClose }}
*The above quotes are for reference only
Real-time News
2026-10-27
Qianhong Pharmaceutical said at an earnings briefing that its QHRD106 injection for acute ischemic stroke is in the closing stage of Phase IIb trials. After completing communications with China’s Center for Drug Evaluation (CDE), the The company will
Qianhong Pharmaceutical said at an earnings briefing that its QHRD106 injection for acute ischemic stroke is in the closing stage of Phase IIb trials. After completing communications with China’s Center for Drug Evaluation (CDE), the The company will promptly advance Phase III trials and related marketing-authorization filings.
2026-10-27
China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said b
China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations list and barred from participating in national drug procurement for four years; JSC Farmak and its applicant Shanghai Liyi Pharmaceutical Technology Co. were likewise listed and barred for two years.
2026-10-27
Moody's analyst said future rating actions will depend on whether Japan's recent resilience can withstand future shocks.
Moody's analyst said future rating actions will depend on whether Japan's recent resilience can withstand future shocks.
2026-10-27
Moody's analysts: Future rating actions depend on whether Japan's latest resilience can withstand future shocks.
Moody's analysts: Future rating actions depend on whether Japan's latest resilience can withstand future shocks.
2026-10-27
MOODY'S sovereign analyst says Japan is showing signs of sustained growth and stable inf.
MOODY'S sovereign analyst says Japan is showing signs of sustained growth and stable inf.
2026-10-27
Moody's sovereign analysts: Japan is showing signs of sustained growth and stable inflation.
Moody's sovereign analysts: Japan is showing signs of sustained growth and stable inflation.
1
...
313
314
315
316
317
...
319
Real-time Quotes
Real-time News
Chat with us
, powered by
LiveChat